Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 65
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02117167 | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | ||
| NCT00930891 | Bevacizumab in Extensive Small Cell Lung Cancer | ||
| NCT00775385 | TAilored Post-Surgical Therapy in Early Stage NSCLC | ||
| NCT01700582 | French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | ||
| NCT03591731 | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | ||
| NCT05154344 | RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) | ||
| NCT06840834 | Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy | ||
| NCT03030131 | Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer | ||
| NCT06908993 | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | ||
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | ||
| NCT07420439 | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | ||
| NCT02784171 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | ||
| NCT04920981 | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC | ||
| NCT04621188 | Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | ||
| NCT07759492 | Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer | ||
| NCT04108026 | Immunotherapy in Patient With Poor General Condition | ||
| NCT00198393 | Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV | ||
| NCT01102231 | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) | ||
| NCT06937905 | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) | ||
| NCT01631136 | Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer | ||
| NCT03469960 | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | ||
| NCT00198406 | A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER. | ||
| NCT02727335 | Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements | ||
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | ||
| NCT01850303 | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT02724696 | French National Observatory of Patients With Thymic Epithelial Tumor | ||
| NCT04111705 | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | ||
| NCT02473133 | Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC | ||
| NCT00198341 | Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up | ||
| NCT00198380 | Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature | ||
| NCT04526782 | ENCOrafenib With Binimetinib in bRAF NSCLC | ||
| NCT01705184 | Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. | ||
| NCT01556191 | Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR | ||
| NCT02716272 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients | ||
| NCT04775095 | BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation | ||
| NCT03977194 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | ||
| NCT00298415 | Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) | ||
| NCT03304093 | Immunotherapy by Nivolumab for HIV+ Patients | ||
| NCT04233021 | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation | ||
| NCT00775307 | Adjuvant Pazopanib in Stage I NSCLC | ||
| NCT06053099 | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) | ||
| NCT00433563 | Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer | ||
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | ||
| NCT00651456 | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study | ||
| NCT02273375 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | ||
| NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer | ||
| NCT05856695 | Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | ||
| NCT07234058 | Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma | ||
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | ||
| NCT02716311 | Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer |
